Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Shigeki Ohtake"'
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, on behalf of Japan Adult Leukemia Study Group
Publikováno v:
HemaSphere, Vol 7, Iss 6, p e899 (2023)
Externí odkaz:
https://doaj.org/article/d7e5a0987ca542338d175708144ea6e9
Autor:
Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 66-75 (2020)
Abstract: The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo CBF-AML patients, aged 16 to 64 years, who achieved complete remission. They rece
Externí odkaz:
https://doaj.org/article/d8f98219f90f425d95e4fd4f64876f2b
Autor:
Yuki Fujioka, Daisuke Sugiyama, Itaru Matsumura, Yosuke Minami, Masatomo Miura, Yoshiko Atsuta, Shigeki Ohtake, Hitoshi Kiyoi, Yasushi Miyazaki, Hiroyoshi Nishikawa, Naoto Takahashi
Publikováno v:
Cancers, Vol 13, Iss 23, p 5904 (2021)
Treatment-free remission (TFR) has become a therapeutic goal in chronic myeloid leukemia (CML), and approximately half of the patients with chronic phase-CML (CML-CP) with deep molecular remission (DMR) by tyrosine-kinase inhibitors (TKIs) have achie
Externí odkaz:
https://doaj.org/article/e877c71ed0c34e60965b985606eb7a35
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Publikováno v:
Blood. 140:6030-6032
Autor:
Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Elsa Bernard, Shigeki Ohtake, June Takeda, Maria Creignou, Lanying Zhao, Manabu Kusakabe, Yuhei Shibata, Nobuhiko Nakamura, Mizuki Watanabe, Nobuhiro Hiramoto, Yusuke Shiozawa, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Yoshida, Nobuyuki Kakiuchi, Hideki Makishima, Masahiro Marshall Nakagawa, Kensuke Usuki, Mitsumasa Watanabe, Kazunori Imada, Hiroshi Handa, Masataka Taguchi, Toru Kiguchi, Kazuma Ohyashiki, Takayuki Ishikawa, Akifumi Takaori-Kondo, Hisashi Tsurumi, Senji Kasahara, Shigeru Chiba, Tomoki Naoe, Satoru Miyano, Elli Papaemmanuil, Yasushi Miyazaki, Eva Hellström Lindberg, Seishi Ogawa
Publikováno v:
Blood Advances.
Azacitidine is a mainstay of therapy for MDS-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their post-treatment clone size. We enr
Autor:
Fumihiko Hayakawa, Tomoko Hata, Yasushi Miyazaki, Shigeki Ohtake, Mitsuhiro Matsuda, Masahiro Onoda, Isamu Sugiura, Yukiyasu Ozawa, Maki Hagihara, Yukio Kobayashi, Tomoki Naoe, Toru Sakura, Noriko Doki, Hiroyuki Fujita, Hisayuki Yokoyama, Yoshihiro Hatta, Ryuko Cho, Yuichi Ishikawa, Nobuhiro Hiramoto, Masatsugu Tanaka, Toshiro Ito, Nobuaki Dobashi, Shinichi Kako, Tsuyoshi Kamae, Yasuhiro Taniguchi, Masaaki Tsuji, Shin Fujisawa, Yasunori Ueda, Yoshiko Atsuta, Satoshi Nishiwaki, Daiki Hirano, Youko Suehiro
Publikováno v:
Blood Advances
Key Points Dasatinib-based 2-step induction resulted in a 100% CR rate with minimal toxicities and 53% MRD negativity.This protocol treatment increased the number of HSCTs in CR1, thereby improving 3-year EFS.
Visual Abstract
The standard t
Visual Abstract
The standard t
Autor:
Ken Ishiyama, Noriharu Nakagawa, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). However, whether bridging therapy (BRT) including azacitidine (AZA) and combination chemotherapy (CCT) prior to allo-SCT s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b739a6d580d7bb7f9e5237a9f936326c
https://doi.org/10.21203/rs.3.rs-2271688/v1
https://doi.org/10.21203/rs.3.rs-2271688/v1
Autor:
Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hitoshi Minamiguchi, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki, the Japan Adult Leukemia Study Group
Publikováno v:
Cancers, Vol 12, Iss 6, p 1444 (2020)
Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance
Externí odkaz:
https://doaj.org/article/aebcdb6e50ea4cdbbbb66af997b35a70
Autor:
Yasushi Miyazaki, Naomi Kawashima, Heiwa Kanamori, Maki Hagihara, Norio Asou, Kensuke Usuki, Hitoshi Kiyoi, Tomoki Naoe, Miki Kobayashi, Shigeki Ohtake, Yoshiko Atsuta, Masashi Sawa, Akio Kohno, Yuichi Ishikawa, Tomoya Maeda, Masaki Hayashi, Itaru Matsumura, Hiroshi Matsuoka, Akihiro Tomita, Emiko Sakaida, Yukiyasu Ozawa
Publikováno v:
Cancer Science
In this phase II multicenter study (JALSG AML209‐FLT3‐SCT), we aimed to prospectively elucidate the role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) at first complete remission (CR1) for FLT3‐internal tandem duplication
Autor:
Yasushi, Miyazaki, Toru, Kiguchi, Shinya, Sato, Kensuke, Usuki, Ken, Ishiyama, Yoshikazu, Ito, Takahiro, Suzuki, Jun, Taguchi, Shigeru, Chiba, Nobuaki, Dobashi, Akihiro, Tomita, Hironori, Harada, Hiroshi, Handa, Shigeo, Horiike, Tomoya, Maeda, Mitsuhiro, Matsuda, Motoshi, Ichikawa, Tomoko, Hata, Sumihisa, Honda, Satoshi, Iyama, Hitoshi, Suzushima, Yukiyoshi, Moriuchi, Toshiro, Kurokawa, Kenichi, Yokota, Shigeki, Ohtake, Takahiro, Yamauchi, Itaru, Matsumura, Hitoshi, Kiyoi, Tomoki, Naoe
Publikováno v:
International journal of hematology. 116(2)
The hypomethylating agent azacitidine (AZA) significantly extends overall survival (OS) in patients with higher risk myelodysplastic syndromes (MDS), when compared with other conventional care regimens, including supportive care and low-dose and inte